Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 162

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 162
---
4,588,780  
     13.7%

*Less than 1%

(1)Unless otherwise indicated, the business address of each of
the following entities or individuals is c/o Drugs Made In America Acquisition Corp., 1 East Broward Boulevard, Suite 700, Fort Lauderdale,
FL 33301.

(2)Drugs Made In America Acquisition LLC, our sponsor, is the record
holder of the shares reported herein. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over
the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor,
except to the extent of her pecuniary interest therein.

Restrictions on Transfers of Founder Shares
and Private Placement Units

The founder shares and the Private Placement Units, including the underlying
private shares and private rights, are subject to transfer restrictions pursuant to lock-up provisions in the letter agreement with us
entered into by our initial shareholders. Those lock-up provisions provide that such securities are not transferable or salable until
the earlier of: (i) with respect to 50% of the founder shares and Private Placement Units, the earlier of six months after the date of
the consummation of our initial business combination and the date on which the closing price of our ordinary shares equals or exceeds
$12.50 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any
20 trading days within any 30-trading day period commencing after our initial business combination and (ii) with respect to the remaining
50% of the founder shares and Private Placement Units, six months after the date of the consummation of our initial business combination,
or earlier, in either case, if, subsequent to our initial business combination, we consummate a liquidation, merger, share exchange or
other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities
or other property, except in each case (a) to our officers or directors, any affiliates or family members of any of our officers or directors,
any members of our sponsor, or any affiliates of our sponsor, (b) in the case of an individual, by gift to a member of the individual’s
immediate family or to a trust, the beneficiary of which is a member of the individual’s immediate family or an affiliate of such
person, or to a